Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling by around 50 points on Monday.

Shares of Esperion Therapeutics, Inc. ESPR rose sharply in today’s pre-market trading.

The U.S. FDA approved broad new labels for Esperion's NEXLETOL® and NEXLIZET® to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use.

Esperion Therapeutics shares jumped 12.7% to $2.58 in pre-market trading.

Here are some big stocks recording gains in today’s pre-market trading session.

• Forge Global Holdings, Inc. FRGE shares gained 22.8% to $2.86 in pre-market trading after gaining 13% on Friday.
• Canopy Growth Corporation CGC gained 19.5% to $9.17 in pre-market trading. The German government approved legislation which legalizes the possession and cultivation of cannabis beginning April 1.
• Masimo Corporation MASI shares climbed 13.8% to $153.65 in pre-market trading after the company announced it has authorized management to evaluate a proposed separation of its consumer business. The company also reaffirmed its first-quarter and FY24 guidance.
• Cronos Group Inc. CRON rose 9.6% to $2.86 in pre-market trading after gaining 9% on Friday.
• Nuvation Bio Inc. NUVB gained 8.2% to $2.50 in pre-market trading after gaining 3% on Friday.
• Tilray Brands, Inc. TLRY gained 5.2% to $2.43 in pre-market trading after jumping 18% on Friday. Germany approved the legalization of cannabis for adult use.
• WK Kellogg Co KLG rose 4.8% to $19.49 in pre-market trading.
• GoodRx Holdings, Inc. GDRX shares climbed 4.1% to $6.85 in pre-market trading. Wells Fargo analyst Stan Berenshteyn upgraded GoodRx from Equal-Weight to Overweight and announced a $10 price target.
• Century Aluminum Company CENX shares gained 3.6% to $13.69 in pre-market trading.

Now Read This: Investor Optimism Improves Slightly; Dow Jumps Over 250 Points

Don’t forget to check out our premarket coverage here